Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 284

1.

Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo.

Perez-Vargas J, Amirache F, Boson B, Mialon C, Freitas N, Sureau C, Fusil F, Cosset FL.

Nat Commun. 2019 May 8;10(1):2098. doi: 10.1038/s41467-019-10117-z.

2.

Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization.

Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, Aizaki H, Ryo A, Yun JH, Park SY, Ohtani N, Muramatsu M, Iwami S, Tanaka Y, Sureau C, Wakita T, Watashi K.

Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8487-8492. doi: 10.1073/pnas.1811064116. Epub 2019 Apr 5.

PMID:
30952782
3.

Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets.

Verrier ER, Weiss A, Bach C, Heydmann L, Turon-Lagot V, Kopp A, El Saghire H, Crouchet E, Pessaux P, Garcia T, Pale P, Zeisel MB, Sureau C, Schuster C, Brino L, Baumert TF.

Gut. 2019 Mar 4. pii: gutjnl-2018-317065. doi: 10.1136/gutjnl-2018-317065. [Epub ahead of print]

PMID:
30833451
4.

Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes.

Fukano K, Tsukuda S, Oshima M, Suzuki R, Aizaki H, Ohki M, Park SY, Muramatsu M, Wakita T, Sureau C, Ogasawara Y, Watashi K.

Front Microbiol. 2019 Jan 8;9:3257. doi: 10.3389/fmicb.2018.03257. eCollection 2018.

5.

A Single Adaptive Mutation in Sodium Taurocholate Cotransporting Polypeptide Induced by Hepadnaviruses Determines Virus Species Specificity.

Takeuchi JS, Fukano K, Iwamoto M, Tsukuda S, Suzuki R, Aizaki H, Muramatsu M, Wakita T, Sureau C, Watashi K.

J Virol. 2019 Feb 19;93(5). pii: e01432-18. doi: 10.1128/JVI.01432-18. Print 2019 Mar 1.

6.

[Hepatitis delta virus replication and the role of the small hepatitis delta protein S-HDAg].

Abeywickrama-Samarakoon N, Cortay JC, Sureau C, Alfaiate D, Levrero M, Dény P.

Med Sci (Paris). 2018 Oct;34(10):833-841. doi: 10.1051/medsci/2018209. Epub 2018 Nov 19. Review. French.

PMID:
30451678
7.

ICTV Virus Taxonomy Profile: Deltavirus.

Magnius L, Taylor J, Mason WS, Sureau C, Dény P, Norder H, Ictv Report Consortium.

J Gen Virol. 2018 Dec;99(12):1565-1566. doi: 10.1099/jgv.0.001150. Epub 2018 Oct 12.

PMID:
30311870
8.

De Novo Macrocyclic Peptide Inhibitors of Hepatitis B Virus Cellular Entry.

Passioura T, Watashi K, Fukano K, Shimura S, Saso W, Morishita R, Ogasawara Y, Tanaka Y, Mizokami M, Sureau C, Suga H, Wakita T.

Cell Chem Biol. 2018 Jul 19;25(7):906-915.e5. doi: 10.1016/j.chembiol.2018.04.011. Epub 2018 May 17.

9.

Reactivation of a Vaccine Escape Hepatitis B Virus Mutant in a Cambodian Patient During Anti-Hepatitis C Virus Therapy.

Fusco DN, Ganova-Raeva L, Khudyakov Y, Punkova L, Mohamed A, Cheon SSY, Koirala P, Andersson KL, Jourdain G, Sureau C, Chung RT, Lauer G.

Front Med (Lausanne). 2018 Apr 30;5:97. doi: 10.3389/fmed.2018.00097. eCollection 2018.

10.

Common and Distinct Capsid and Surface Protein Requirements for Secretion of Complete and Genome-Free Hepatitis B Virions.

Ning X, Luckenbaugh L, Liu K, Bruss V, Sureau C, Hu J.

J Virol. 2018 Jun 29;92(14). pii: e00272-18. doi: 10.1128/JVI.00272-18. Print 2018 Jul 15.

11.

A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction.

Saso W, Tsukuda S, Ohashi H, Fukano K, Morishita R, Matsunaga S, Ohki M, Ryo A, Park SY, Suzuki R, Aizaki H, Muramatsu M, Sureau C, Wakita T, Matano T, Watashi K.

Biochem Biophys Res Commun. 2018 Jun 22;501(2):374-379. doi: 10.1016/j.bbrc.2018.04.187. Epub 2018 May 11.

PMID:
29730285
12.

Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.

Kaneko M, Futamura Y, Tsukuda S, Kondoh Y, Sekine T, Hirano H, Fukano K, Ohashi H, Saso W, Morishita R, Matsunaga S, Kawai F, Ryo A, Park SY, Suzuki R, Aizaki H, Ohtani N, Sureau C, Wakita T, Osada H, Watashi K.

Sci Rep. 2018 Feb 9;8(1):2769. doi: 10.1038/s41598-018-20987-w.

13.

Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks.

Quinet J, Jamard C, Burtin M, Lemasson M, Guerret S, Sureau C, Vaillant A, Cova L.

Hepatology. 2018 Jun;67(6):2127-2140. doi: 10.1002/hep.29737. Epub 2018 Feb 23.

14.

Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.

Giersch K, Bhadra OD, Volz T, Allweiss L, Riecken K, Fehse B, Lohse AW, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M.

Gut. 2019 Jan;68(1):150-157. doi: 10.1136/gutjnl-2017-314713. Epub 2017 Dec 7.

PMID:
29217749
15.

Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro.

Beilstein F, Blanchet M, Vaillant A, Sureau C.

J Virol. 2018 Jan 30;92(4). pii: e01416-17. doi: 10.1128/JVI.01416-17. Print 2018 Feb 15.

16.

Correction for Kwei et al., "Impaired Virion Secretion by Hepatitis B Virus Immune Escape Mutants and Its Rescue by Wild-Type Envelope Proteins or a Second-Site Mutation".

Kwei K, Tang X, Lok AS, Sureau C, Garcia T, Li J, Wands J, Tong S.

J Virol. 2017 Nov 30;91(24). pii: e01655-17. doi: 10.1128/JVI.01655-17. Print 2017 Dec 15. No abstract available.

17.

Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.

Guillot C, Martel N, Berby F, Bordes I, Hantz O, Blanchet M, Sureau C, Vaillant A, Chemin I.

PLoS One. 2017 Jun 21;12(6):e0179697. doi: 10.1371/journal.pone.0179697. eCollection 2017.

18.

Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.

Giersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse AW, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, Lütgehetmann M.

Sci Rep. 2017 Jun 16;7(1):3757. doi: 10.1038/s41598-017-03946-9.

19.

Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity.

Shimura S, Watashi K, Fukano K, Peel M, Sluder A, Kawai F, Iwamoto M, Tsukuda S, Takeuchi JS, Miyake T, Sugiyama M, Ogasawara Y, Park SY, Tanaka Y, Kusuhara H, Mizokami M, Sureau C, Wakita T.

J Hepatol. 2017 Apr;66(4):685-692. doi: 10.1016/j.jhep.2016.11.009. Epub 2016 Nov 25.

PMID:
27890789
20.

A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins.

Tsukuda S, Watashi K, Hojima T, Isogawa M, Iwamoto M, Omagari K, Suzuki R, Aizaki H, Kojima S, Sugiyama M, Saito A, Tanaka Y, Mizokami M, Sureau C, Wakita T.

Hepatology. 2017 Apr;65(4):1104-1116. doi: 10.1002/hep.28952. Epub 2017 Jan 17.

PMID:
27863453
21.

Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes.

Verrier ER, Colpitts CC, Bach C, Heydmann L, Zona L, Xiao F, Thumann C, Crouchet E, Gaudin R, Sureau C, Cosset FL, McKeating JA, Pessaux P, Hoshida Y, Schuster C, Zeisel MB, Baumert TF.

Cell Rep. 2016 Oct 25;17(5):1357-1368. doi: 10.1016/j.celrep.2016.09.084.

22.

HDV RNA replication is associated with HBV repression and interferon-stimulated genes induction in super-infected hepatocytes.

Alfaiate D, Lucifora J, Abeywickrama-Samarakoon N, Michelet M, Testoni B, Cortay JC, Sureau C, Zoulim F, Dény P, Durantel D.

Antiviral Res. 2016 Dec;136:19-31. doi: 10.1016/j.antiviral.2016.10.006. Epub 2016 Oct 19.

PMID:
27771387
23.

Unusual Features of Sodium Taurocholate Cotransporting Polypeptide as a Hepatitis B Virus Receptor.

Li J, Zong L, Sureau C, Barker L, Wands JR, Tong S.

J Virol. 2016 Aug 26;90(18):8302-13. doi: 10.1128/JVI.01153-16. Print 2016 Sep 15.

24.

The hepatitis delta virus: Replication and pathogenesis.

Sureau C, Negro F.

J Hepatol. 2016 Apr;64(1 Suppl):S102-S116. doi: 10.1016/j.jhep.2016.02.013. Review.

PMID:
27084031
25.

Hepatitis B virus receptors and molecular drug targets.

Verrier ER, Colpitts CC, Sureau C, Baumert TF.

Hepatol Int. 2016 Jul;10(4):567-73. doi: 10.1007/s12072-016-9718-5. Epub 2016 Mar 15. Review.

PMID:
26979861
26.

A unique monoclonal antibody for therapeutic use against chronic hepatitis B: not all antibodies are created equal.

Sureau C.

Gut. 2016 Apr;65(4):546-7. doi: 10.1136/gutjnl-2015-310978. Epub 2015 Nov 26. No abstract available.

PMID:
26611231
27.

A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.

Kaneko M, Watashi K, Kamisuki S, Matsunaga H, Iwamoto M, Kawai F, Ohashi H, Tsukuda S, Shimura S, Suzuki R, Aizaki H, Sugiyama M, Park SY, Ito T, Ohtani N, Sugawara F, Tanaka Y, Mizokami M, Sureau C, Wakita T.

J Virol. 2015 Dec;89(23):11945-53. doi: 10.1128/JVI.01855-15. Epub 2015 Sep 16.

28.

A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses.

Verrier ER, Colpitts CC, Bach C, Heydmann L, Weiss A, Renaud M, Durand SC, Habersetzer F, Durantel D, Abou-Jaoudé G, López Ledesma MM, Felmlee DJ, Soumillon M, Croonenborghs T, Pochet N, Nassal M, Schuster C, Brino L, Sureau C, Zeisel MB, Baumert TF.

Hepatology. 2016 Jan;63(1):35-48. doi: 10.1002/hep.28013. Epub 2015 Oct 6.

PMID:
26224662
29.

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F.

Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10. Review.

PMID:
25670809
30.

SKI-1/S1P inhibitor PF-429242 impairs the onset of HCV infection.

Blanchet M, Sureau C, Guévin C, Seidah NG, Labonté P.

Antiviral Res. 2015 Mar;115:94-104. doi: 10.1016/j.antiviral.2014.12.017. Epub 2015 Jan 5.

PMID:
25573299
31.
32.

Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.

Blanchet M, Sureau C, Labonté P.

Antiviral Res. 2014 Jun;106:111-5. doi: 10.1016/j.antiviral.2014.03.017. Epub 2014 Apr 6.

PMID:
24717262
33.

Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation.

Kwei K, Tang X, Lok AS, Sureau C, Garcia T, Li J, Wands J, Tong S.

J Virol. 2013 Feb;87(4):2352-7. doi: 10.1128/JVI.02701-12. Epub 2012 Dec 5. Erratum in: J Virol. 2017 Nov 30;91(24):.

34.

A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant.

Sureau C, Salisse J.

Hepatology. 2013 Mar;57(3):985-94. doi: 10.1002/hep.26125. Epub 2013 Feb 15.

PMID:
23161433
35.

[In law, the other].

Sureau C.

Gynecol Obstet Fertil. 2012 Aug;40 Suppl 1:1-2. doi: 10.1016/S1297-9589(12)70016-4. French. No abstract available.

PMID:
23141590
36.

Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples.

Servant-Delmas A, Mercier-Darty M, Ly TD, Wind F, Alloui C, Sureau C, Laperche S.

J Clin Virol. 2012 Apr;53(4):338-45. doi: 10.1016/j.jcv.2012.01.003. Epub 2012 Jan 31.

PMID:
22296790
37.

ABCB6 is dispensable for erythropoiesis and specifies the new blood group system Langereis.

Helias V, Saison C, Ballif BA, Peyrard T, Takahashi J, Takahashi H, Tanaka M, Deybach JC, Puy H, Le Gall M, Sureau C, Pham BN, Le Pennec PY, Tani Y, Cartron JP, Arnaud L.

Nat Genet. 2012 Jan 15;44(2):170-3. doi: 10.1038/ng.1069.

38.

Overestimation of incidence of hepatitis B virus mixed-genotype infections by use of the new line probe INNO-LiPA genotyping assay.

Mercier M, Laperche S, Girault A, Sureau C, Servant-Delmas A.

J Clin Microbiol. 2011 Mar;49(3):1154-6. doi: 10.1128/JCM.01888-10. Epub 2010 Dec 22.

39.

The use of hepatocytes to investigate HDV infection: the HDV/HepaRG model.

Sureau C.

Methods Mol Biol. 2010;640:463-73. doi: 10.1007/978-1-60761-688-7_25.

PMID:
20645068
40.

The pre-S1 and antigenic loop infectivity determinants of the hepatitis B virus envelope proteins are functionally independent.

Le Duff Y, Blanchet M, Sureau C.

J Virol. 2009 Dec;83(23):12443-51. doi: 10.1128/JVI.01594-09. Epub 2009 Sep 16.

41.

Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion.

Garcia T, Li J, Sureau C, Ito K, Qin Y, Wands J, Tong S.

J Virol. 2009 Nov;83(21):11152-65. doi: 10.1128/JVI.00905-09. Epub 2009 Aug 12.

42.

A function essential to viral entry underlies the hepatitis B virus "a" determinant.

Salisse J, Sureau C.

J Virol. 2009 Sep;83(18):9321-8. doi: 10.1128/JVI.00678-09. Epub 2009 Jul 1.

43.

[2008 update of the 8th Consensus Development Conference of the Francophone Society of Medical Emergencies of 1999. The treatment of adult renal colic by the emergency services and in emergency rooms].

El Khebir M, Fougeras O, Le Gall C, Santin A, Perrier C, Sureau C, Miranda J, Ecollan P, Bagou G, Trinh-Duc A, Traxer O; Sous commission de veille scientifique de la SFMU.

Prog Urol. 2009 Jul;19(7):462-73. doi: 10.1016/j.purol.2009.03.005. Epub 2009 May 21. French.

PMID:
19559376
44.

In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.

Villet S, Billioud G, Pichoud C, Lucifora J, Hantz O, Sureau C, Dény P, Zoulim F.

Gastroenterology. 2009 Jan;136(1):168-176.e2. doi: 10.1053/j.gastro.2008.09.068. Epub 2008 Oct 7.

PMID:
18996386
45.

[Assisted reproduction project: legal constraints, ethical considerations].

Sureau C.

J Gynecol Obstet Biol Reprod (Paris). 2008 Aug;37 Suppl 1:S34-5. doi: 10.1016/S0368-2315(08)73850-X. French.

46.

Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent.

Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, Sacunha A, Larrey D, Dubuisson J, Coste J, McKeating J, Maurel P, Fournier-Wirth C.

J Virol. 2008 Jan;82(1):569-74. Epub 2007 Oct 17.

48.

Myristoylation signal transfer from the large to the middle or the small HBV envelope protein leads to a loss of HDV particles infectivity.

Abou-Jaoudé G, Molina S, Maurel P, Sureau C.

Virology. 2007 Aug 15;365(1):204-9. Epub 2007 Apr 25.

49.
50.

Hepatitis B virus subviral envelope particle morphogenesis and intracellular trafficking.

Patient R, Hourioux C, Sizaret PY, Trassard S, Sureau C, Roingeard P.

J Virol. 2007 Apr;81(8):3842-51. Epub 2007 Jan 31.

Supplemental Content

Loading ...
Support Center